#USA #New York #Rosen Law Firm #Soleno Therapeutics #SLNO

Rosen Law Firm Investigates Soleno Therapeutics

The Rosen Law Firm, a leading global investor rights law firm, has announced an ongoing investigation into potential securities claims concerning Soleno Therapeutics, Inc. (NASDAQ: SLNO). This pursuit comes in light of serious allegations that Soleno may have disseminated materially misleading business information to its investors. With the implications of such claims being quite significant, the firm encourages both current and former shareholders to inquire about their rights and possible compensation.

Background of the Investigation

On August 15, 2025, a report released by Investing.com drew attention to a sharp decline in Soleno Therapeutics' stock value, which fell notably following a short report issued by Scorpion Capital. The report indicated alarming safety concerns regarding the company's recently approved treatment for Prader-Willi syndrome, known as VYKAT XR. Investors were particularly unsettled as the report indicated that the treatment might face market withdrawal or a drastic reduction in new prescriptions. Following this information, the stock saw a downturn of 7.4% on that same day, and an additional drop of 4.9% was noted on the next trading day.

As the situation developed, it became apparent that Soleno Therapeutics' investors could be eligible for compensation. Under a contingency fee arrangement, which allows them to pursue their claims without upfront costs, those who purchased Soleno securities may join the class action. Rosen Law Firm is poised to assist in the recovery of losses incurred by investors during this tumultuous time.

Why Choose Rosen Law Firm?

Rosen Law Firm stands out as a champion for investor rights, with a proven track record in representing shareholders in securities class actions and derivative litigation. Over the years, the firm has successfully represented investors across the globe, demonstrating an impressive history of achieving substantial settlements. Notably, it has secured the highest-ever securities class action settlement originating from a Chinese company. Since 2013, the firm has consistently ranked in the top tier by ISS Securities Class Action Services, recovering hundreds of millions for its clients, including an astonishing $438 million in 2019 alone. Furthermore, founding partner Laurence Rosen was recognized in 2020 as one of Law360’s Titans of the Plaintiffs’ Bar.

Today's investors would do well to choose counsel that possesses not only experience but also the resourcefulness to decisively handle complex securities litigation. Not every firm reaches the same level of recognition or effectiveness; hence, selecting the right legal representation is crucial for ensuring a favorable outcome.

Next Steps for Investors

For those interested in pursuing their claims against Soleno Therapeutics, you can seamlessly join the forthcoming class action by visiting the Rosen Law Firm's submission page or reaching out directly via toll-free number 866-767-3653. Additionally, interested parties can email [email protected] for further details or clarification regarding the legal proceedings.

Rosen Law Firm keeps its clients and the public informed about potential class actions and updates through social media channels. Followers are encouraged to stay connected via LinkedIn, Twitter, or Facebook for real-time updates.

Conclusion

This developing situation calls for immediate action among investors connected to Soleno Therapeutics, Inc. The legal landscape surrounding securities and investor rights can be complicated, but with the right representation from a reputable firm like Rosen Law Firm, shareholders can navigate this tumultuous period with greater confidence. With their substantial expertise and commendable history of success, Rosen Law Firm is well-equipped to represent the interests of affected investors against potentially misleading corporate practices.